The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients
|ClinicalTrials.gov Identifier: NCT02069210|
Recruitment Status : Unknown
Verified February 2014 by Sirilak Suksompong, Mahidol University.
Recruitment status was: Not yet recruiting
First Posted : February 24, 2014
Last Update Posted : February 24, 2014
|Condition or disease||Intervention/treatment|
|Infection After Transfusion||Other: Blood transfusion|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
Patients receive blood transfusion during operation
Other: Blood transfusion
Intraoperative blood transfusion
- Immunologic parameters [ Time Frame: 7 days ]
Blood level of the following parameters on preoperative, postoperative day 1, 3, 5-7.
- IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, Il-7, IL-8, Il-9, Il-10, Il-12, Il-13, IL-15, Il-17,basic FGF (Fibroblast growth factors).
- Cell Analytics - (mononuclear) T-Cells incl. killer cells, CD2, CD3, CD4, CD8, CD25, CD30, CD19, CD20, CD138, CD56, CD56, CD303, CD304, NK cytotoxicity (non-radioisotope), CTL cytotoxicity (non-radioisotope), T cell proliferation, B cell, T cell.
- To determine the effect of red cell transfusion on clinical relevant outcome parameters, such as myocardial infarction, infection rate, and length of hospital stay. [ Time Frame: 1 month ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02069210
|Contact: Sirilak Suksompong, MDfirstname.lastname@example.org|
|Sirilak Suksompong||Not yet recruiting|
|Bangkok, Thailand, 10700|
|Contact: Sirilak Suksompong, MD 66891534806 email@example.com|
|Study Director:||Sirilak Suksompong, MD||Department of Anesthesiology, Faculty of medicine Siriraj Hospital, Mahidol University|